Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease

Pizzi, Carmine; Rutjes, Anne Wilhelmina Saskia; Costa, Grazia Maria; Fontana, Fiorella; Mezzetti, Andrea; Manzoli, Lamberto (2011). Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. American journal of cardiology, 107(7), pp. 972-979. New York, N.Y.: Elsevier 10.1016/j.amjcard.2010.11.017

[img] Text
Pizzi AmJCardiol 2011.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (307kB) | Request a copy

The occurrence of depression in patients with coronary heart disease (CHD) substantially increases the likelihood of a poorer cardiovascular prognosis. Although antidepressants are generally effective in decreasing depression, their use in patients with CHD is controversial. We carried out a meta-analysis to evaluate the health effects of selective serotonin reuptake inhibitors (SSRIs) versus placebo or no antidepressants in patients with CHD and depression. Observational studies and randomized controlled trials (RCTs) were searched in MEDLINE, EMBASE, PsycINFO, Cochrane Controlled Clinical Trial Register and other trial registries, and references of relevant articles. Primary outcomes were readmission for CHD (including myocardial infarction, unstable angina, and stroke) and all-cause mortality; the secondary outcome was severity of depression symptoms. Seven articles on 6 RCTs involving 2,461 participants were included. One study incorrectly randomized participants, and another was a reanalysis of RCT data. These were considered observational and analyzed separately. When only properly randomized trials were considered (n = 734 patients), patients on SSRIs showed no significant differences in mortality (risk ratio 0.39, 95% confidence interval 0.08 to 2.01) or CHD readmission rates (0.74, 0.44 to 1.23) compared to controls. Conversely, when all studies were included, SSRI use was associated with a significant decrease in CHD readmission (0.63, 0.46 to 0.86) and mortality rates (0.56, 0.35 to 0.88). A significantly greater improvement in depression symptoms was always apparent in patients on SSRIs with all selected indicators. In conclusion, in patients with CHD and depression, SSRI medication decreases depression symptoms and may improve CHD prognosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Rutjes, Anne

ISSN:

0002-9149

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:22

Last Modified:

10 Sep 2017 16:34

Publisher DOI:

10.1016/j.amjcard.2010.11.017

PubMed ID:

21256471

Web of Science ID:

000289275500003

BORIS DOI:

10.7892/boris.7593

URI:

https://boris.unibe.ch/id/eprint/7593 (FactScience: 212888)

Actions (login required)

Edit item Edit item
Provide Feedback